Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Müllhaupt, Beat; Bruggmann, Philip; Bihl, Florian; Blach, Sarah; Lavanchy, Daniel; Razavi, Homie; Robbins Scott, Sarah; Semela, David; Negro, Francesco (2018). Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030? PLoS ONE, 13(12):e0209374.

Bruggmann, Philip; Blach, Sarah; Deltenre, Pierre; Fehr, Jan; Kouyos, Roger; Lavanchy, Daniel; Müllhaupt, Beat; Rauch, Andri; Razavi, Homie; Schmid, Patrick; Semela, David; Stoeckle, Marcel; Negro, Franco (2017). Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030. Swiss Medical Weekly, 147:w14543.

Bruggmann, Philip; Negro, Francesco; Bihl, Florian; Blach, Sarah; Lavanchy, Daniel; Müllhaupt, Beat; Razavi, Homie; Semela, David (2015). Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Medical Weekly, 145:w14221.

Pfeil, Alena M; Reich, Oliver; Guerra, Ines M; Cure, Sandrine; Negro, Francesco; Müllhaupt, Beat; Lavanchy, Daniel; Schwenkglenks, Matthias (2015). Cost-effectiveness analysis of Sofosbuvir compared to current standard treatment in Swiss patients with chronic Hepatitis C. PLoS ONE, 10(5):e0126984.

Müllhaupt, Beat; Bruggmann, Philip; Bihl, Florian; Blach, Sarah; Lavanchy, Daniel; Razavi, Homie; Semela, David; Negro, Francesco (2015). Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE, 10(6):e0125214.

This list was generated on Mon Sep 23 20:10:23 2019 CEST.